Tuesday, 16 Jul 2019

You are here

ACR 2017 - Day 2 Highlights

In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated. He showed impressive data by Feig, wherein adolescents with hypertension and a high SUA were treated with either placebo or urate lowering therapy (ULT). Only those treated with ULT had a lowering of the BP.  However these impressive results in kids, have yet to be duplicated in adults. Other studies show that those patients with the highest quartiles of SUA are at significantly higher risk for adverse CV outcomes. But these findings are inconsistent. Despite some of these intriguing reports, the belief is that AH may be associated with multiple comorbities but there is little proof of direct causality. His best advice was to treat asymptomatic hyperuricemia when the benefits clearly outweigh the potential risks of ULT.

Another plenary session presentation focused on CFZ533, a novel, non-depleting anti-CD40 Mab that was shown to be clinically effective in patients with Sjogren’s syndrome. In a small (32 patient) trial the study drug was superior to placebo at week 12 and 24 using the ESSDAI (a 12 organ domain composite efficacy score for Sjogren’s outcomes).

Chambers et al from OTIS presented their prospective analysis of the Mother to Baby study of biologic use during pregnancy in women with inflammatory disorders. 1156 infants were followed until 1 year post delivery.  Biologic exposed (490) were compared to unexposed (221) with disease and a nondisease control group (412). Serious infections in the infants were not increased when comparing the exposed (2.3%), unexposed (4%) and controls (1.9%). The same results were seen when only looking at those exposed in the 3rd trimester and those exposed with steroids as well.

A cohort of 4796 knee osteoarthritis (OA) patients enrolled in the OA initiative (OAI) were studied for the effect of intraarticular corticosteroid injections.  Follow-up studies showed that intraarticular steroids were associated with a significant 2.7-5.7 fold increased risk of radiographic worsening or knee replacement.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.